Clear All
757 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Not yet assigned Inotuzumab Ozogamicin Besponsa 0.9 mg Immunotherapy Drug Antibody Conjugate CD22 No 2017 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
NA Selpercatinib Retevmo 40mg, 80mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2020 In Use
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Trifluridine and Tipiracil Lonsurf 15/6.14 mg Chemotherapy Antimetabolite Pyrimidine Analog Yes 2015 In Use
NA Aprepitant Emend 40 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
Lazertinib Lazcluze 80mg, 240mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2024 In Use
NA Avapritinib Ayvakit 300mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
Capivasertib Truqap 160mg, 200mg Chemotherapy AKT Inhibitor AKT 1/2/3 Yes 2023 In Use
NA Afatinib Gliotrif 30 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Cysteamine Bitartrate Cystagon 50mg, 150mg Chemotherapy Cystine-Depleting Agent Yes 1994 In Use
NA Ceritinib Zykadia 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2014 In Use
Maribavir Livtencity 200mg Ancillary Therapy Miscellaneous Agent CMV Antiviral Yes 2021 In Use
NA Nilutamide Anadron, Nilandron 150 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 1996 In Use
NA Alpelisib Piqray 150mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Avapritinib Ayvakit 200mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Estramustine Phosphate Sodium Emcyt 140 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1981 In Use
Niraparib and Abiraterone Akeega Multiple Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Yes 2023 In Use
Nirogacestat Ogsiveo 50mg, 100mg, 150mg Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Yes 2023 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
NA Duvelisib Copiktra 15mg, 25mg Chemotherapy Enzyme Inhibitor PI3K Yes 2018 In Use
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Lapatinib Tykerb 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2007 In Use
NA Crizotinib Xalkori 250 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
NA Tivozanib Fotivda 0.89mg, 1.34mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2021 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.